Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-6: COVID-19 Outpatient Randomized Trial
NCT04885530Phase 3Completed
- Start
- Jun 2021
- Primary completion
- Apr 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CHILD-IVITAB, fluvoxamine, fluticasone propionate nasal spray, montelukast and liquid metformin (Aspargo Labs) in coronavirus disease 2019 (COVID-19) (14 arms). Primary endpoint: Total Number of Participants Randomized Within Each Appendix. Started Jun 2021; status: completed.
02
Drugs
CHILD-IVITABfluvoxaminefluticasone propionate nasal spraymontelukastliquid metformin (Aspargo Labs)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04885530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04885530.